The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
Open accessAbstract
The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Cited by
Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status
Won, J. C., Lee, J. H., Kim, J. H., Kang, E. S., Won, K. C., Kim, D. J., & Lee, M.-K. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0017 · Cited by 299
Self-citationKyoung, D.-S., & Kim, H.-S. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.2.103 · Cited by 259
Kim, J., & Hur, M.-H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168439 · Cited by 51
Self-citationQin, J., Chen, Y., Guo, S., You, Y., Xu, Y., Wu, J., Liu, Z., Huang, J., Chen, L., & Tao, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.543627 · Cited by 47
Development of various diabetes prediction models using machine learning techniques
Shin, J., Kim, J., Lee, C., Yoon, J. Y., Kim, S., Song, S., & Kim, H.-S. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0115 · Cited by 29
Self-citation
Metadata
- Authors
- Kim, M. K., Ko, S.-H., Kim, B.-Y., Kang, E. S., Noh, J., Kim, S.-K., Park, S.-O., Hur, K. Y., Chon, S., Moon, M. K., Kim, N.-H., Kim, S. Y., Rhee, S. Y., Lee, K.-W., Kim, J. H., Rhee, E.-J., Chun, S., Yu, S. H., Kim, D. J., Kwon, H.-S., Park, K. S., & Committee of Clinical Practice Guidelines, K. D. A.
- Venue
- Diabetes & Metabolism Journal
- Publisher
- Korean Diabetes Association
- Published
- 2019
- Volume
- 43
- Issue
- 4
- Pages
- 398
- ISSN
- 2233-6079 (ISSN-L)
- 2233-6087
- OpenAlex
- W2969746584
- Cited by
- 216
- References
- 14
- FWCI
- 29.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea. https://app.cochat.ai/papers/10.4093/dmj.2019.0137
- The paper
- Kim, M. K., Ko, S.-H., Kim, B.-Y., Kang, E. S., Noh, J., Kim, S.-K., Park, S.-O., Hur, K. Y., Chon, S., Moon, M. K., Kim, N.-H., Kim, S. Y., Rhee, S. Y., Lee, K.-W., Kim, J. H., Rhee, E.-J., Chun, S., Yu, S. H., Kim, D. J., . . . Committee of Clinical Practice Guidelines, K. D. A. (2019). 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2019.0137
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
